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Class I MHC antigens play a key role in the vertebrate immune defense system.
They are transmembrane proteins expressed on nucleated cells ofmost tissues. In
certaintumor typesthe expression ofclass I HLA (thehuman class I MHC) is often
reduced orabrogated. This was observed forinstance in melanomas, small cell lung
carcinomas, neuroblastomas, and colon carcinomas (for review see reference 1). In
some tumor types low class I HLA expression correlates with poor prognosis (2,
3). Involvement ofclass I HLAin human tumorprogression is suggestedby findings
in rodent tumors that the level of class I MHC expression strongly influences the
oncogenic and metastatic potential oftumor cells (reviewed in reference 4). Two
different mechanisms with counteracting effects have been described.
First, tumorcellswith lowclass I MHC expression could escape from destruction
bycytotoxic T cells, asT cells onlyrecognize specific antigens when theyarepresented
on the cell surface by class I MHC molecules. In a number ofmurine tumor model
systems, variant cells with a reduced class I MHC expression are more oncogenic
and metastatic after inoculation in syngeneic animals than their counterparts with
normal class I MHC expression (5-7). Re-establishment ofclass I MHC expression
by gene transfer or treatment with IFN-y reduces the malignancy ofthese tumor
cells (8, 9).
Second, in other experimental tumor systems it was found that variant cells with
a reduced classI MHC expression are in vitro more susceptible to lysis by NK cells
than cells with a normal class I MHC expression (10, 11). In vivo these variant cells
were found tobe lessmalignant that the strongly class I-positive parental cells from
which they were selected.
Recently, we have shown that in human melanoma cells the class I HLA expres-
sion is strongly downregulated by a high expression ofthe c-myc oncogene (12, and
Versteeg, R., L. T. C. Peltenburg, A. C. Plomp, and P. I. Schrier, manuscript sub-
mitted for publication). This was demonstrated in a numberofhighc-myc-expressing
melanoma cell lines as well as in melanoma lines with a low c-myc expression that
we transfected with c-myc expression vectors. A similar effect was reported for the
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N-myc gene in a rat neuroblastoma cell line (13). High expression of myc genes is
found in many tumors. c-myc can contribute to cellular transformation and can en-
hance the metastatic potential of tumorcells (reviewed in reference 14). The finding
that c-myc reduces class I HLA expression implies that this gene, primarily involved
in oncogenesis, in addition may influence the immune recognition of the resultant
tumor cells. The reduced class I HLA expression could lead to an escape from de-
struction by cytotoxic T cells, or, on the other hand, to an increased susceptibility
to lysis by NK cells.
A complicating factor in the study of the downregulation of class I HLA by c-myc
is the high complexity of the class I genes. At the three class I loci, A, B, and C,
20, 40, and 10 alleles, respectively, have been defined (15). Most individuals are het-
erozygous for each locus. For the class I HLA-A and -B loci, no explicit differences
in expression or function have been described so far, which could be due to the fact
that the >70 class I HLA alleles are highly homologous and difficult to discriminate.
We wondered whether c-myc suppresses the HLA-A, -B, and -C loci to the same
extent. Here, we report a highly differential regulation ofclass I HLA loci by c-myc,
inducing a strong imbalance in the expression of HLA-A and HLA-B in human
melanomas and melanoma cell lines. This mechanism has important consequences
for the complex interactions between tumor cells and the immune system.
Materials and Methods
Tissue Culture.
￿
Melanoma cell lines(12) and mouse L cells (16,17) were cultured in DMEM
+ 10% FCS. The EBVimmortalized B cell line was cultured in RPMI + 10% FCS. Treat-
ment with rIFN-1' (Boehringer Ingelheim, Ingelheim am Rhein, BRD) was for 48 h with
500 U/ml.
Northern Blotting Procedures.
￿
Mouse L cells and melanoma cells were harvested by trypsini-
zation and immediately quick frozen. Total RNA was isolated by the LiCl/ureum method
(18). RNA (20 pg/lane) was separated by electrophoresis through an 15o' agarose-formaldehyde
gel and transferred onto nitrocellulose. Hybridizations were performed with probes radiola-
beled by the random primer method (19). The following probes were used: c-myc, a Cla I/Eco
RI fragment of a human genomic clone, spanning most of exon 3 (20); GAPDH, a rat
glyceraldhyde-3-phosphate dehydrogenase cDNA (21); -Y-Actin, a mouse cDNA (gift of A.
Bernards, MGH Cancer Center, Boston, MA); class I HLA-A locus, a 1 .3-kb Pvu II/Xba
I fragment of a genomic A2 clone, spanning the 3'-untranslated region (22); class I HLA-B
locus, a 358-bp Pst I/Pvu II fragment of a B8 cDNA clone, spanning the 3'-untranslated
region (22); class I HLA-C locus, a 432-bp Ssp I/Bam HI fragment of a Cwt genomic clone,
spanning the 3'-untranslated region (17). Hybridizations were performed in 50% formamide,
0.75 M NaCl, 50 mM NaH2PO4, 5 mM EDTA, 0.1% SDS, 0.1% BSA, 0.1% ficoll, 0.1%
polyvinylpyrrolidon, and 200,ug/ml salmon sperm DNA. The c-myc, GAPDH, and .y-actin
probes were hybridized at 42 °C. The class I HLA-A, -B, and -C probes were hybridized
at 59°C, 610C, and 610C, respectively. After hybridization the filters were washed four times
for 30 min in 2x SSC, 0.1% SDS at 50°C.
Antibodies.
￿
W6/32 (23) is an mAb recognizing all (32-microglobulin-bound class I HLA
antigens. 4E is an mAb recognizing all class I HLA-B locus antigens and from the class I
HLA-A locus the alleles A29 up to and including A33 (24). The mAb 4B recognizes exclu-
sively the classI HLA-A2 and -A28 alleles (24). HC-A2 is an mAb recognizing mainly dena-
tured H chains ofclassI HLA-A loci (Siam, N. J., Th. N. Vroom, P. J. Peters, E. B. Pastoors,
and H . L. Ploegh, manuscript submitted for publication). The HC-10 mAb recognizes both
native and denatured H chains of mainly class I HLA-B loci (25).
Isoelectric Focusing.
￿
Melanoma cells and B cells were labeled with "S-methionine and ly-
sates were prepared as described (26). Samples with equal 35S incorporation (10 P.Ci) wereVERSTEEG ET AL.
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precipitated with the mAb W6/32 bound to protein A-Sepharose beads. The protein
A-Sepharose complexes were spun through a 30% sucrose cushion and the pellet was washed
in neuraminidase buffer (50 mM NaAc, 1 mM CaC12, pH 5 .0). Pellets were resuspended
in neuraminidase buffer and neuraminidase was added (2 U/ml) (type VIII; Sigma Chem-
ical Co., St. Louis, MO). Samples were shaken for 3 h at 37°C. The samples were centrifuged
and the pellets resuspended in 30 pl IEF buffer (9.5 M urea, 2% [vol/vol] ampholyte 3 .5-10
[LKB Instruments, Inc., Gaithersburg, MD], 2% [vol/vol] 0-ME) and subjected to IEF ac-
cordingto Neefjes et al. (27). Afterwards, gels were washed in fixative (7 % HAc, 5% MeOH),
soaked in Amplify (Amersham Corp., Arlington Heights, IL), and dried.
HLA Typing .
￿
EBVimmortalized B cell lines and PBL were typed for classI HLA-A, -B,
and -C antigens, making use of alloantisera (derived from parous women) and complement
lysis according to the standard National Institutes of Health technique (28). Melanoma cell
lines were typed for class I HLA-A, -B, and -C antigens according to an adaptation of this
method (29). Before typing, cell lines 136-2, 453A, and 603 were treated for 48 h with 500
U/ml IFN-y. For a number of HLA antigens, we performed control experiments comparing
IEF patterns ofmelanoma cell lines with those ofwell-typed control cell lines (Table I). Also,
precipitations with antisera HC-10 and 4E (see above) followed by IEF served as an extra
control for the identification ofcertain antigen specificities (Table I). The 603 cell line is posi-
tive for HLA-B53 or -B63, but we were unable to discriminate between these antigens as
the used alloantisera are crossreactive and both HLA types have a nearly identical mobility
on IEF gels. 136-2 cells gave only a weak reaction with alloantisera for A31, and therefore,
the assignment of this antigen is based on the finding that the protein is precipitable with
the 4E antibody, but not with the HC-10 antibody, indicating an A29 to A33 specificity. Final
identification followed from comparison ofthe IEF pattern of 136-2 cells with that of control
cells, which showed the identical mobility of the 136-2 band with the A31 protein (data not
shown). The experiments enabling the HLA typing of the melanoma cell lines are summa-
rized in Table I.
FACSAnalysis.
￿
5 x 105 cells were incubated for 30 min with a saturating concentration
of the appropriate antibody. After washing, the cells were incubated with 1 :10 dilution of
FITC-labeled goat anti-mouseIgG (Nordic, Tilburg, The Netherlands). After washing, fluores-
cence of the cells was measured on a FACSTAR cytofluorimeter (Becton Dickinson & Co.,
Mountain View, CA). All incubations and wash steps were performed at O'C.
Staining of Tissue Sections.
￿
Cryostat sections 4 tim thick were cut from deep-frozen mela-
noma lesions. Consecutive sections were air dried, fixed in 100% acetone for 10 min, and
stained with an indirect three-step immunoperoxydase procedure (30). In short, tissue sec-
tions were sequentially incubated with mAbs, with a rabbit anti-mouse Ig antiserum (Dako
Corp., SantaBarbara, CA), and with a horseradish peroxidase-conjugated swine anti-rabbit
Ig antiserum (Dako Corp.); 3-amino-9-ethylcarbozole was used as a substrate. Counterstaining
was done with hematoxylin.
DNA Transfections and Vectors.
￿
Transfection of the 518A cell line is described in detail else-
where (Versteeg, R., L. T C. Peltenburg, A. C. Plomp, and P I. Schrier, manuscript sub-
mitted for publication). Briefly, cotransfection was performed (31) with PSV2neo and a
derivative ofpBR 322 containingc-myc exon 2 + 3 under control ofthe SV40 enhancer/pro-
motor as well as the dihydrofolate reductase (DHFR) gene undercontrol ofthe methallothionein
promotor. Selection was performed with 800,ug/ml G418. One G418-resistant clone was fur-
ther cultured in DMEM + 10% dialyzed FCS and steadily increasing concentrations of
methotrexate, resulting in a cell culture resistant to 200 nM methotrexate (518A-myc-200).
Results
In previous experiments we found an inverse relationship between the expression
levels of class I HLA and the c-myc oncogene in a panel of 11 melanoma cell lines
(12). To investigate whether the downmodulation of class I HLA by c-myc holds for
all three class I HLA loci, we analyzed the expression of the individual loci in three
representative melanoma cell lines with a high c-myc expression. We first measured624
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TABLE I
HLA Typing of Melanoma Cell Lines
Summary of the experiments enabling the HLA typing of melanoma cell lines. +, positive
reaction; - , negative reaction; t , weak positive reaction.
the class I HLA expression at the mRNA level, using locus-specific probes derived
ofthe 3'-untranslated region ofthe HLA-A2, -B8, and Cw2 genes, respectively. This
region is strongly conserved within the different alleles of a particular locus, but
shows a relatively high divergence between the three different loci. As a control for
the specificity ofthe probes, we performed aNorthern blottinganalysis oftotal RNA
isolated from three mouse L cell lines expressing transfected class I HLA-A2, -B7,
and -Cw2, genes, respectively. Under high stringency conditions the three probes
hybridize locus specifically (Fig. 1, lanes 10, 11, and 12). On the same filter we ana-
lyzedthemRNA offivemelanoma cell lines. Two celllineswithlowc-mycexpression
(IGR 39D and 518A; Fig. 1, lanes 8 and 9, respectively) express all three class I
HLA loci. The three cell lines with a high c-myc expression (603, 136-2, and 453A;
Fig. 1, lanes 2, 4, and 6, respectively) show hardly any hybridization with the B
locus probe, but a good hybridization with the A locus probe. The C locus probe
hybridizes with the RNA from cell lines 136-2 and 453A, but hardly with the RNA
from cell line 603. From the patient from whom the melanoma cell line 603 was
derived, we also established aB cellline(B 606) by immortalizationwith EBV. Com-
parison of the RNAs from the tumor cell line and the B cell line (Fig. 1, lanes 2
and 1) shows that the B and C loci are switched off in the tumor line, while the
A locus expression is hardly affected.
We also analyzed RNAs isolated after IFN-y treatment of the three high c-myc-
expressing melanoma lines (Fig. 1, lanes3, 5, and 7). In allcases astrong hybridiza-
tion is seen with the B and C probes . This shows first that the B and C alleles of
these patients are well recognized by our probes, and second, that the suppression
of these alleles is a regulatory phenomenon that can be overruled by IFN-'r treat-
ment. The combined results show that in the high c-myc-expressing cell lines, the
HLA-B locus is switched off, while the HLA-A locus expression is hardly affected.
Cell
line
HLA
antigens
Typed on
tumor cells
Typed on
PBL/B cells
IEF
control
HC-10
reactive
4E
reactive
518A Al + + + - ND
A2 + + + - ND
B8 + + ND + ND
IGR39 Al + ND + - -
B62 + ND + + +
453A A2 + ND + - -
B55 + ND ND + +
603 A24 + +_ + - -
A30 + + ND - +
B13 + + + t +
B53/63 + + ND + +
136-2 A31 + ND + - +
B56 + ND ND + +
B62 + ND + + +VERSTEEG ET AL .
￿
625
FIGURE 1 .
￿
mRNA expression of class I HLA-A, -B, and -C loci in five melanoma cell lines as-
sayed by Northern blotting. Lanes 10, 11, and 12 were loaded with RNAs from mouse L cells
expressing transfected class I HLA-A2, -B7, and -Cw2 genes, respectively . Lanes 2, 4, and 6,
melanoma cell lines 603, 136-2 and 453A ; lanes 3, 5, and 7, melanoma cell lines 603, 136-2,
and 453A treated for 48 h with IFN-y; lanes 8 and 9, the melanoma cell lines IGR 39D and
518A; lane 1, theB cell lineB606 . The filterwas sequentially hybridized with probes as indicated
in the figure. As a control for the quantification, the ethidium bromide-stained blot gel is shown .
The situation with respect to the C locus is not clear, as two cell lines with high
c-mychave normal expression (453Aand 136-2) and one (603) seems to have down-
regulated HLA-C expression .
ExclusiveExpression ofHLAAAlleles.
￿
As thethree class IHLAloci are multi-allelic
systems, we further investigated whether the differential regulation ofA and B loci
holds for allA and all B alleles present in our cell lines . Class I HLA proteins of
different alleles can be separated by IEF (27) . Combined with the identification of
the class I HLA alleles by classical HLA typing using alloantisera, the IEF tech-
niqueenabled us to analyze theexpression ofindividual classI alleles (the data resulting
in theHLA typing of the melanoma cell lines are given in Materials and Methods) .
IFN-y-treated and untreated cells of the melanoma line 603 and the B cell line B
606 (derived from the same patient) were labeled with 35S-methionine . Cell lysates
were precipitated with themAb W6/32, which recognizes all class I HLA proteins
associated with N2-microglobulin (23) . SomeC locus products are poorly precipi-626
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tated as they do not associate effectively with a2-microbulin (32) . The immune
precipitates were subjected to IEF . Both the IFN--y-treated melanoma line 603 and
the B cell line B 606 show, besides the a2-microglobulin band, the same four pre-
dominating bands (Fig . 2 A, lanes 2 and 3) .A fifthband is nonspecifically immuno-
precipitated, as it is also found in acontrol precipitation ofB 606 with pre-immune
serum (Fig . 2A, lane 4) . Two ofthe four specifically precipitated bands are not found
in the untreated tumor cell line (Fig. 2 A, lane 1), even after a longer exposure of
the filter (Fig. 2 A, lane 1'). The UN-y-treated tumor cell line 603 and the B cell
line B 606 were typed as HLA-A24, -A30, -B13, and -B53 or -B63 (we were unable
to discriminate between B53 and B63 ; see Materials and Methods) . This enabled
us to assign the bands as indicated in Fig . 2A . Clearly, no B antigens are precipi-
tated from the tumor cells with W6/32. HLA-B antigens were also not found after
precipitation with the HC-10 antibody recognizing free HLA-B chains (25), thus
excluding the possibility that these antigens are present in the cells in a free, not
a2-microglobulin-bound, form (data not shown) . We conclude that both HLA-B al-
leles are switched off in the 603 cells, while theHLA-A antigens are well expressed,
albeit less strongly than in the B cell line .
A similar IEF gel made with precipitates of melanoma cell line 136-2 shows be-
sides the a2-microglobulin band only one major band (Fig . 2 B lane 1) that can be
assigned to the HLA-A31 antigen (see Materials and Methods) . After IFN-'r treat-
ment astrongand aweak extraband appear, which based on HLA-typing data could
be identified as B56 and B62 proteins, respectively (Fig . 2 B, lane 2) . As bothHLA-
B bands are not found with W6/32, norwith the HC-10 antibody (data not shown),
FIGURE 2 .
￿
Analysis ofthe expression of individual class I HLA alleles in three melanoma cell
lines . Untreated or IFN-.y-treated (48 h, 500 U/ml) cells were labeled with s5S-methionine and
lysates of equal 35S incorporation were precipitated with W6/32 and subjected to IEF Ascrip-
tion of the indicated class I HLA alleles is based on data described in Materials and Methods .
(A) Precipitations from the 603 melanoma cell line andthe B cell line B 606 derived from the
same patient . Lane 1, 603 cells; lane 2, 603, after IFN-y treatment; lane 3, B cell line B 606 ;
lane 4, control precipitation of B 606 with pre-immune serum ; lane 1', long exposure of lane
1 . (B) Precipitations from the 136-2 melanoma cell line. Lane 1, 136-2 ; lane 2, 136-2, afterINF,y
treatment . (C) Precipitations of the 453A cell line . Lane 1, control precipitation of 453A with
pre-immune serum ; lane 2, 453A; lane 3, control precipitation with pre-immune serum of 453A
treated with IFN-.y ; lane 4, 453A cells after treatment with IFN-.y .VERSTEEG ET AL.
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weconclude that in 136-2 cells, unless treated with IFN-y, only the HLA-A31 allele
is expressed.
The IEF pattern of453A cellsshows, besidesa nonspecific band also precipitated
with pre-immune serum (Fig. 2 C, lane 1), only the bands of HLA-A2 and 02-
microglobulin (Fig. 2 C, lane 2). IFN-,y treatment results in the appearance of a
new band (Fig. 2 C, lane 4), which we identified as HLA-B55 (see Materials and
Methods). Other faint bands seen in Fig. 2 C, lane 4areprobably HLA-C products.
As only one A and one B allele are expressed, we guess that 453A cells are homozy-
gous for HLA-A and -B or have lost the class I HLA region ofone chromosome
6. In 453A cells the B55 band is not found with the W6/32 antibody, nor with the
HC-10 antibody (data not shown). We conclude that in this cell line also, only the
HLA-A locus is expressed.
TheseIEFdatashowthatinthree melanoma cell lines withhigh c-mycexpression,
theAalleles are well expressed, while all B alleles are largely switched off. This favors
the idea that in melanoma cell lines the suppression ofclass I HLA is locus specific
and not just allele specific.
Only HLAA Locus Products Are Expressed on the Cell Surface.
￿
Forthe biological func-
tion ofclass I HLA proteins, only the expression on the cell membrane is relevant.
We therefore used flow cytometryto assay for cell surface expression ofclassIHLA.
With the antibody W6/32 (recognizing, as well, HLA-A and -B) a high amount of
cell surface labeling could be detected on the high c-myc-expressing melanoma cell
line 453A (Fig. 3 A). The same result was obtained with the mAb 4B, specific for
HLA-A2 (24), which is in agreement with the protein chemistry data, i.e., 453A
being of the HLA-A2 specificity (Fig. 3 B). Strikingly, antibody 4E, which recog-
nizes all HLA-B antigens but not HLA-A2 (24), reacts only very weakly with the
453A cell line (Fig. 3 C). After IFN-'Y treatment this antibody gives a strong signal
(Fig. 3 D). This shows that in cell line 453A, hardly any HLA-B antigens are ex-
pressed on the cell surface, except after IFN-'r treatment.
Preferential Downmodulation ofthe HLA-B Locus by Transfected c-myc Genes.
￿
Previously
we have shownthat c-mycsuppresses the class I HLA mRNA and proteinexpression
(12). The antibody used in those studies (B1.23.2; reference 33) happened to have
astrong preference forB locusproducts. Forthehybridization ofthe Northernblots
we used at that time a cDNA probe of the B7 allele. It is generally assumed that
this probe recognizes all class I HLA transcripts, but we recently found that it hy-
bridizes mainly with B and C locus transcripts, even under low stringency condi-
tions (datanot shown). Our detailed analysis ofthe class I HLA expression in three
highc-myc-expressing melanoma cell lines suggests that c-mycdownmodulatesmainly
B locus expression. To test this, we investigated the downregulation ofthe HLA-A
and -B loci in c-myc transfectants ofthe IGR 39D and 518A melanoma cell lines.
First, cellline IGR 39D(low c-myc, highclass I HLA) and the threec-myc-Tunsfcted
clones, 6, 7, and 3, which we described before (12), were analyzed. Flow cytometry
after labeling with the HLA-B-specific mAb 4E of IGR 39D and clones 6, 7, and
3 shows a relative fluorescence of 100%, 46%, 34%, and 14%, respectively (data not
shown). Lysates ofthese cells after labeling with 3'S-methionine were precipitated
with W6/32 and subjected to IEF. IGR 39D was typed as HLA-A1 and HLA-B62,
and both antigens arewell expressed (Fig. 4A). In the c-myctransfectants, the bands
of the B62 antigen are strongly reduced, while the Al antigen expression is only628
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FIGURE 3.
￿
Cell surface expression of class I HLA-A and -B antigens on 453A melanoma cells
as measured by FAGS analysis. They-axis gives the relative cell number; the x-axis gives the
relative fluorescence intensity in a logarithmic scale. Cells were incubated with specific mAbs
followed by FITC-labeled goat anti-mouse IgG(curves 2). Negative controls were stained omit-
ting the first antibody (curves 1). (A) staining with the mAb W6/32, recognizing both HLA-A
and HLA-B antigens; (B) staining with mAb 4B, specific for the HLA-A2 allele; (C) staining
with the mAb 4E, recognizing all HLA-B alleles; (D) same as C, after IFN-'Y treatment of the
453A cells.
slightly downmodulated (Fig. 4 A) . The difference is strongest in clone 3, which
has the highest c-myc expression (12). In this clone, the A locus expression is not
completely unaffected, which suggests the possibility that at even higher c-myc con-
centrations further suppression of the A locus might occur.
We have also transfected a c-mycconstruct to melanoma cell line 518A (Versteeg,
R., L. T. C. Peltenburg, A. C. Plomp, and P. I. Schrier, manuscript submitted for
publication). To test for locus-specific downregulation, we analyzed 518A (low c-myc,
high class I HLA), 518A-neo (a PSV2neo-transfected control), and 518A-myc-200,
aclone selected for high expression of thetransfected c-myc gene (see Materials and
Methods). PBL of the patient from whom the 518A melanoma cell line was derived
were typed as HLA-A1, -A2, and (homozygous) -B8. The 518A and 518A-neo cell
lines show astrong expression of allthree antigens (Fig. 4 B, lane 1 and 2). However,
in the 518A-myc-200 transfectant, the expression of the B8 antigen is strongly re-
duced, while the expression of the Al and A2 antigens remained unaltered (Fig.
4 B, lane 3).
From these transfection experiments we conclude that c-myc suppresses the B locusVERSTEEG ET AL .
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FIGURE 4 .
￿
Expression ofclass IHLA al-
leles in c-myc-transfected melanoma cell
lines. Cells were labeled with 35S-methio-
nine and lysates were precipitated with
W6/32and subjected to IEF . Assignment
of the indicated class IHLA antigens is
based on HLA typing data described in
MaterialsandMethods . (A)IEF ofprecipi-
tates fromIGR39Dandthreec-myc-trans-
fected derivatives. Clones 6, 7, and3 have
thesame numbering as described earlier
(12) and are shown here in order of de-
creasing class IHLA-B expression as deter-
minedby FACS analysis (relative toIGR
39D, respectively, 46%, 34%, and 14%).
(B) Precipitations from 518A and c-myc-
transfected derivatives . Lane 1, 518A; lane
2, 518A-neo, a PSV2neo-transfected con-
trol of518A; lane 3, 518A-myc-200, aclone
of 518A cotransfected with PSV2neo and
a c-myc/DHFR construct, which was se-
lected for a highly increased c-myc expres-
sion (see Materials and Methods) .
alleles much more strongly than theA locus alleles, which is in agreement with the
results found in the three melanoma cell lines with high c-myc expression .
Melanoma Tumor Lesions also Lack HLA-B Expression.
￿
For the interpretation of the
biological function of our present findings, it is highly relevant to establish whether
locus-specific downregulation is also found in vivo. Therefore, we determined class
I HLA expression in the primary tumor from which we established cell line 453A .
Successive tissue sections were stained with the antibodies HC-A2, preferentially
recognizingAlocusproducts (Stam,N.J., Th . N. Vroom,PJ. Peters,E. B. Pastoors,
andH . L. Ploegh, manuscript submitted forpublication) and HC-10, preferentially
recognizingBlocus products (25) . The sections stainedwith HC-A2 (Fig. 5 A) have
a homogeneous positive reaction pattern, but in the sections stained with HC-10
(Fig . 5 B), only a few areas are positive, showingthat the vast majority of thetumor
cells has no B locus expression. In all cells, however, theA locus is expressed. Also,
the metastatic tumor lesion from which the 603 melanoma cell line was established
(a subcutaneous metastasis) was investigated . Staining of successive tissue sections
with theHC-A2 and HC-10 antibodies revealed in this tumor, as well, an exclusive
expression of HLA-A (data not shown) .630
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FIGURE 5 .
￿
Immunohistochemical analysis of the HLA-A and HLA-B expression on the pri-
mary cutaneous melanoma from which cell line 453A was derived. Consecutive frozen sections
were stained with the anti HLA-A antibodyHC-A2 (A) or the anti HLA-B antibody HC-10 (B) .
Note the marked staining of a single nest of tumor cells in B. Sections were counterstained with
hematoxylin to visualize the nuclei .VERSTEEG ET AL.
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Discussion
Inthis work we show, forfivemelanoma celllineswith a highexpression ofendog-
enous or transfected c-myc genes, that certain class I HLA alleles are preferentially
switched off. This observation was made for the B8, B13, B53/63, B55, B56, and
B62 alleles. Alleles that are not or hardly switched off were identified as Al, A2,
A24, A30, and A31. Suppression ofthe C locus was found by comparing the mela-
noma cell line 603 and a B cellline ofthe same patient, but was not evidentin other
cell lines (see Fig. 1). We conclude that suppression ofclass I HLA by c-myc is re-
stricted mainly to the B locus and possibly the C locus. Comparison of melanoma
cell lines expressing increasing amounts oftransfected c-myc genes suggests that the
A locus does not stay completely unaffected, but its suppression is limited relative
to the suppression ofthe B locus. In three melanoma cell lines with high c-myc ex-
pression, this preferential downregulation results in the virtually complete absence
ofB locus products, while the A locus is strongly expressed. The same differential
expression patternwas foundin twosurgically removed melanomalesions, suggesting
that the differential suppression ofthe class I loci by c-myc can have biological rele-
vance for the functioning of the class I HLA system in human melanomas.
Because low class I HLA expression or high c-mycexpression are found in alarge
variety of human tumors, it is fairly likely that a differential expression ofclass I
HLA loci occurs in more tumor types than melanomas. In many studies the class
I HLA expression on tumor lesions was quantified, but only in a few tumor types
was acorrelation between low class I HLAexpression and malignancy ordifferenti-
ation grade found (2, 3). However, such studies usually did not discriminate be-
tween thethree class I HLAloci. As illustrated by ourexperiments, theW6/32 anti-
bodymay givea strong signal,whileHLA-B expression was absent. Therefore, tumors
with reduced expression of only one class I locus are probably overlooked so far.
The use of locus-specific antibodies could give a better insight in the relation be-
tween class I HLA expression and malignancy oftumors. Interestingly, two examples
ofallele-specific downregulation ofclass I HLA in tumors have been described very
recently. In some Burkitt lymphomas, suppression of HLA-All was described (34),
and in some colon carcinomas, absence ofHLA-A2 was found (35). A differential
expression ofHLA-A and -B transcripts was reported for the Molt-4 cell line (36).
Whether c-myc is involved in these processes is presently unknown.
Melanoma-specific cytotoxic T cells, which are class I HLA restricted, have been
isolated and cloned from human melanoma lesions (37, 38). In these studies it was
not investigated whether the tumors had high c-myc expression, nor was it estab-
lished by which class I locus products the tumor antigens were presented to cyto-
toxicT cells. Ourresults predict that melanoma cells with tumor antigens presented
by HLA-A are, irrespective of their c-myc expression, good targets for cytotoxic T
cells. However, we expect that HLA-B-restricted cytotoxic T cells will be unable to
kill high c-myc-expressing melanoma cells. There is evidence that class I MHC-re-
stricted cytotoxic Tcells are involved inthestrong antitumoreffects ofLAKtherapy
(39). Recent studiesby Rosenberget al. (40)suggest that the population ofmelanoma-
infiltratinglymphocytes used inimmunotherapylargely consists ofclass I HLA-re-
stricted cytotoxic T cells. A thorough analysis ofclass I HLA expression on tumor
cells, as describedhere, should reveal whether suppression ofparticular class I HLA
loci correlates with apoorresponse to immunotherapy withtumor-infiltrating lym-
phocytes.632
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Selective downmodulation of specific class I loci was not observed previously in
human tissues and, therefore, it is generallysupposed that theclassIloci arecoregu-
lated and exert identical biological functions. Assuming that the preferential sup-
pression ofHLA-Bby c-mychas abiological function, wewondered whetherforsome
function of class I HLA the A and B loci play a differential role.
Ofthe different functions proposed for class I HLA, the one generally accepted
is the presentation of antigens to cytotoxic T cells. Although our findings predict
thatc-myc-activatedmelanomascould escape fromdestructionby HLA-B-restricted
cytotoxic T cells, this mechanism seems somewhat paradoxical. Such paralysis of
the Tcell surveillance would favortheunrestrained dissemination ofthe most dan-
gerous category of myc-activated tumor cells. As it is unlikely that this bears any
selective advantage to the organism, we think that the reason for c-myc suppressing
HLA-B must not be sought in the fact that this interferes with a possible T cell-im-
'
￿
Another proposed function for class I HLA is modulation of NK
susceptibility oftumorcells: classI MHC-negative variantsoftumor cellswere found
tobemoreprone to NK lysis than theoriginaltumorcellswithnormal class I MHC
expression (1û, 11, 41). We recentlyfoundthat c-myc-transfected melanomacellswith
an abrogated HLA-B expression are more sensitive to NK lysis than the parental
cell lines (Versteeg, R., L. T C. Peltenburg, A. C. Plomp, and P. I. Schrier, manu-
script submitted for publication). This suggests that the suppression ofHLA-B by
c-myccould function as a mechanism by which cells with an aberrant c-mycexpres-
sion are recognized and destroyed by NK cells.
Summary
Thec-myconcogenedownregulates class I HLA expression inhuman melanoma.
The major class I HLA antigens are encoded by three loci, A, B, and C, and we
stigatedwhetherthese loci are suppressed equally byc-myc. In three melanoma
lines with high c-mycexpression, we analyzed mRNA, protein, and cell surface
expression ofthe class I HLA antigens. Whereas the HLA-B locus expression was
found to be strongly reduced, the HLA-A locus was expressed normally. Analysis
ofc-myc-transfectedclones oftwomelanoma celllinesconfirmed thatc-mycpreferen-
tially suppresses the class I HLA-B locus. Immunohistochemical analysis of fresh
melanoma lesions also showed thatin thetumors theHLA-A loci are expressednor-
mally, whileonthe majority oftumorcells no HLA-B antigen expression wasfound.
This downregulation may have consequences for the recognition ofmalignant cells
bytumor-infiltrating lymphocytes. Our results predict that HLA-B-restricted cyto-
toxic T cells will be unable to kill high c-myc-expressing melanoma cells.
We thank Maarten vanderKeur forexpert operation ofthe flow cytometer, Lia Schaikwijk
forexcellent assistance in theimmunohistological procedures, andSimone van Bree forHLA
typing.
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